Litigation Details for CMP Development, LLC v. Amneal Pharmaceuticals LLC (D. Del. 2021)
✉ Email this page to a colleague
CMP Development, LLC v. Amneal Pharmaceuticals LLC (D. Del. 2021)
| Docket | ⤷ Sign Up | Date Filed | 2021-04-16 |
| Court | District Court, D. Delaware | Date Terminated | 2023-10-11 |
| Cause | 35:271 Patent Infringement | Assigned To | Maryellen Noreika |
| Jury Demand | None | Referred To | |
| Parties | CMP DEVELOPMENT, LLC | ||
| Patents | 10,493,083; 9,757,394 | ||
| Attorneys | Jonathan D. Ball | ||
| Firms | Young, Conaway, Stargatt & Taylor LLP | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in CMP Development, LLC v. Amneal Pharmaceuticals LLC
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for CMP Development, LLC v. Amneal Pharmaceuticals LLC (D. Del. 2021)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2021-04-16 | 1 | Complaint | for patent infringement of United States Patent Nos. 9,757,394 (“the ’394 patent”), 10,493,083 (“the…the ’083 patent”), 10,624,906 (“the ’906 patent”), 10,660,907 (“the ’907 patent”), and 10,888,570 (“the…the ’570 patent”) (collectively, the “Patents-in-Suit”) under the patent laws of the United States, Title…copy of the ’083 patent is attached hereto as Exhibit B. 33. The ’906 patent, entitled “Spironolactone…copy of the ’906 patent is attached hereto as Exhibit C. 34. The ’907 patent, entitled “Spironolactone | External link to document |
| 2023-02-03 | 109 | Exhibit List | Yes Yes Certified Copy of U.S. Patent No. 10,493,083 Dr. Moreton …Yes Yes Certified File History for 10,493,083 Dr. Jonnalagaddan JTX 7 …/23 Yes Yes Certified Copy of US Patent 10,624,906 Mr. Pipho JTX 2…/23 Yes Yes Certified Copy of US Patent 10,660,907 Dr. Jonnalagaddan JTX…/23 Yes Yes Certified copy of US Patent 10,888,570 Dr. Jonnalagaddan JTX | External link to document |
| 2023-03-13 | 117 | Post Trial Brief | Parent Patents U.S. Patent Nos. 9,757,394 and 10,493,083 … ’906 patent U.S. Patent No. 10,624,906 ’907 patent … U.S. Patent No. 10,660,907 ’570 patent US. Patent No. 10,888,570… ’906 patent; Claims 1 Asserted Claims and 10 of the ’907 patent; claims…common disclosure of the Asserted Patents was filed with the patent office. (Resp. at 26.) Specifically | External link to document |
| 2024-05-07 | 151 | Opinion - Memorandum Opinion | also asserted patent infringement of United States Patent Nos. 9,757,394 and 10,493,083, but those… ’906 patent, claims 1 and 10 of the ’907 patent and claims 1 and 7-10 of the ’570 patent. 3 …States Patent Nos. 10,624,906, 10,660,907 and 10,888,570 (collectively, “the Asserted Patents”). 1 After… infringe the asserted claims of the Asserted Patents. 2 Plaintiff appealed that decision but later stipulated…II. LEGAL STANDARD Section 285 of the Patent Act provides that a “court in exceptional cases | External link to document |
| 2021-04-16 | 4 | Patent/Trademark Report to Commissioner of Patents | Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,757,394; 10,493,083; 10,624,906; … 2021 11 October 2023 1:21-cv-00549 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
